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Abstract. Background: Adult survivors of childhood malignancy are predisposed to late cardiovascular (CV) complications. Our
aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in
long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.
Methods: ADMA and its isomer symmetric dimethylarginine (SDMA) were measured in 25 former ALL patients (aged 18–
28 years) who had survived without recurrent disease  5 years from completing chemotherapy without cranial irradiation, and
in 20 healthy controls (aged 20–31 years).
Results: Characteristics of the both groups were similar, except for lower high-density lipoproteins-cholesterol (HDL-C) in ALL
survivors. Compared to controls, the former ALL patients exhibited significant, albeit small, rises in levels of ADMA (0.63 ±
0.09 [SD] vs. 0.57 ± 0.07 µmol/L; p = 0.016), but not SDMA, with a consequently increased ADMA to SDMA ratio (1.08 ±
0.22 vs. 0.91 ± 0.16; p = 0.004). The effect of former ALL on ADMA was attenuated (intergroup p = 0.10 [ANCOVA]) upon
adjustment for HDL-C (ADMA vs. HDL-C regression coefficient: −0.065 ± 0.030 [SEM]; p = 0.03).
Conclusions: ADMA is elevated in adult childhood ALL survivors, which can reflect late detrimental chemotherapy effects,
partially related to minor lipid profile changes. Whether these subtle ADMA elevations might herald future CV morbidity,
remains to be elucidated.
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1. Introduction
Adult survivors of childhood and adolescencemalig-
nancy are at increased risk of late cardiovascular (CV)
complications [1,2]. Acute lymphoblastic leukemia
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(ALL) is the most common pediatric malignancy and
adult survivors of childhood-onset ALL account for
about 28% of the Childhood Cancer Survival Study
cohort [1]. Among survivors of childhood leukemia
(ALL in about 90%), the relative hazard of congestive
heart failure, myocardial infarction and late-occurring
stroke was increased 4.2-fold, 3.3-fold and 6.4-fold,
respectively, with the reference to the sibling control
groups [3,4]. Additionally, in ALL survivors standard-
ized CV mortality ratio was elevated 4.2-fold compared
with the age-, sex- and year-matchedUSpopulation [1].
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The excessive CV risk in former adult survivors of
childhood ALL is ascribed to obesity, insulin resis-
tance and related components of the metabolic syn-
drome (associated with physical inactivity and growth
hormone (GH) deficiency, mainly secondary to cra-
nial irradiation, but also to chemotherapy by itself) [2,
5–7], low physical fitness and exercise capacity [2,8],
anthracycline-inducedcardiomyopathy [2], endothelial
dysfunction [9,10] and endothelial cell apoptosis [10,
11], as well as methotrexate-dependenthyperhomocys-
teinemia [2,12].
Recently, Dengel et al. [13] described impaired bra-
chial artery flow-mediated dilation (FMD) – a noninva-
sive index of vasodilatory endothelial dysfunction [14,
15], closely reflecting an analogous disorder in the
coronary circulation [16] – in young adult survivors of
childhood-onset ALL irrespective of previous cranial
irradiation. Endothelial dysfunction, largely dependent
on reduced bioavailability of nitric oxide (NO), an en-
dogenous anti-atherogenic molecule, is an antecedent
of atherosclerotic plaques and adverse CV events [17].
Asymmetric dimethylarginine (ADMA), an endoge-
nous inhibitor of NO formation, is associated with
CV risk factors, endothelial dysfunction, early carotid
atherosclerosis and adverse CV events in patients with
overt atherosclerotic CV disease [18,19]. Furthermore,
ADMA predicted adverse outcome over 11–24 years
in low-risk population-based cohorts [20,21].Although
ADMA was elevated in adults with hematological
malignancies, including ALL, prior to initiation of
chemotherapy [22], ADMA concentrations in long-
term ALL survivors have not been reported so far. Our
aim was to estimate blood ADMA levels in young
adult survivors of childhood ALL treated with only
chemotherapy.
2. Materials and methods
2.1. Subjects
We studied 25 young adult patients (median age,
20 years [range, 18–28]) with ALL diagnosed during
childhood who had survived without recurrent disease
for a minimum of 5 years from completing chemother-
apy. All the patients had been treated in a tertiary care
center (Department of Pediatric Oncology and Hema-
tology, Jagiellonian University, Cracow, Poland) ac-
cording to ALL-BFM 90 protocol for the standard-risk
group [23]. None of the subjects received cranial irra-
diation. ALL was diagnosed at the mean age of 8.4 ±
4.1 (SD) years; average interval from ALL diagnosis to
study enrollment was 12.6 ± 2.1 years. The mean time
elapsed since the completion of chemotherapy was 9.5
± 2.2 years (range, 5–13). We also recruited a con-
trol group of young healthy volunteers (median age,
22 years [range, 20–31]), mainly among the personnel
of our hospital, their relatives and medical students.
Exclusion criteria were common for both the groups
and included clinical evidence of atherosclerotic CV
disease, heart failure, hypertension, diabetes, total
cholesterol  6.0 mmol/L, estimated glomerular filtra-
tion rate (eGFR) < 90 mL/min per 1.73 m2 of body-
surface area, chronic coexistent diseases, acute infec-
tions within previous 2 weeks and high-sensitivity C-
reactive protein (hs-CRP) > 5 mg/L. In accordance
with the Declaration of Helsinki, the protocol had been
approved by the ethics committee of our university and
each subject gave written informed consent prior to the
inclusion in the study.
2.2. Study protocol
The protocol was carried out in the morning in the
outpatient clinic of our center (Department of Inter-
nal Medicine and Gerontology, Jagiellonian Universi-
ty, Cracow, Poland). The subjects had been previous-
ly asked to refrain from eating, smoking and alcohol
or caffeine consumption overnight. Demographic and
clinical characteristics were recorded; blood pressure
was measured 3 times on the left arm after 5 min of
rest in a sitting position, values from last two read-
ings were averaged. Then a venous blood sample
was drawn from a left antecubital vein for measure-
ments of erythrocyte sedimentation rate (ESR), com-
plete blood count, hs-CRP, serum glucose, glycosylat-
ed hemoglobin, homocysteine, total cholesterol, low-
density lipoproteins-cholesterol (LDL-C), high-density
lipoproteins-cholesterol (HDL-C), triglycerides and
creatinine. We calculated eGFR by the novel Chron-
ic Kidney Disease Epidemiology Collaboration (CKD-
EPI) formulawhich is more accurate than the Modifica-
tion of Diet in Renal Disease study equation, especially
at higher GFR [24].
Plasma for future determinations of ADMA and
its stereoisomer symmetric dimethylarginine (SDMA)
was separated and frozen at −70◦C until assayed.
ADMA and SDMA were measured by validated [25]
commercially available enzyme-linked immunosorbent
assays (DLD Diagnostika GmbH, Hamburg, Ger-
many). The lower detection limits were 0.05 μmol/L
for ADMA and SDMA and intra-assay and inter-
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Table 1
Comparison of characteristics of ALL survivors and control subjects
Characteristic ALL survivors (n = 25) Controls (n = 20) p-value
Male gender (%) 9 (36%) 8 (40%) 0.79
Smoking habit (%) 5 (20%) 7 (35%) 0.27
Height (cm) 170 ± 9 171 ± 10 0.82
Body mass index (kg/m2) 22.6 ± 3.3 21.8 ± 2.3 0.35
Waist circumference (cm) 75 ± 9 73 ± 10 0.53
Waist-to-hip ratio 0.79 ± 0.07 0.76 ± 0.08 0.33
Mean arterial pressure (mmHg) 87 ± 6 88 ± 6 0.57
eGFR, (mL/min per 1.73 m2) 125 ± 11 120 ± 12 0.12
ESR (mm/h) 4 (2–9) 3 (2–6) 0.27
Hs-CRP (mg/L) 0.6 (0.2–1.1) 0.5 (0.3–1.1) 0.87
Hemoglobin (g/dL) 14.7 ± 1.7 14.5 ± 1.6 0.76
Red blood cells (106/µL) 5.0 ± 0.6 5.0 ± 0.5 0.66
White blood cells (103/µL) 5.9 ± 1.4 5.5 ± 1.2 0.27
Platelets (103 /µL) 225 ± 35 238 ± 42 0.25
LDL-C (mmol/L) 2.3 ± 0.6 2.3 ± 0.6 0.78
HDL-C (mmol/L) 1.5 ± 0.4 1.8 ± 0.5 0.02
Triglycerides (mmol/L) 0.9 (0.7–1.4) 0.5 (0.3–1.1) 0.22
Glucose (mmol/L) 4.5 ± 0.5 4.6 ± 0.5 0.49
Glycosylated hemoglobin (%) 5.3 ± 0.4 5.2 ± 0.5 0.89
Homocysteine (µmol/L) 11.8 ± 6.0 10.3 ± 4.4 0.36
Data are shown as means ± SD, medians (interquartile range) or n (%); p-values < 0.05 in
bold. ALL: acute lymphoblastic leukemia; eGFR: estimated glomerular filtration rate; ESR:
erythrocyte sedimentation rate; Hs-CRP: high-sensitive C-reactive protein; LDL-C: low-density
lipoproteins-cholesterol; HDL-C: high-density lipoproteins-cholesterol.
assay coefficients of variation were 5.7% and 10.3%
(ADMA), and 6.1% and 9.8% (SDMA). According
to the manufacturer, cross-reactivity with L-arginine
and other methylarginines averaged below 0.01–0.02%
(SDMA or ADMA vs. L-arginine),0.44–1.2% (ADMA
vs. SDMA), and 0.7–1.0% (SDMA or ADMA vs. NG-
monomethyl-L-arginine).
2.3. Statistical analysis
Data are presented as means ± SD unless indicated
otherwise for continuous variables with normal distri-
bution, medians and interquartile range (25th and 75th
percentiles) for not normally distributed continuous pa-
rameters and numbers (proportions) for categorical da-
ta. The accordance with a normal distribution was test-
ed by the Kolmogorov-Smirnov test. Intergroup differ-
ences were assessed by the unpaired 2-sided Student’s
t-test or Mann-Whitney U test for continuous variables
and Fisher’s exact test for proportions.
Analysis of variance (ANOVA) and covariance
(ANCOVA) were applied to estimate interaction ef-
fects between ALL history and gender or self-reported
smoking on ADMA and SDMA as well as to adjust
for covariates for which the p-value in a univariate
analysis was  0.15. Effects of continuous covariates
were represented by non-standardized regression coef-
ficients (β, mean ± SEM) corresponding to the change
in a dependent variable for an increase of one unit of
measurement in the covariate. Uniformity of variance
was confirmed by Levene’s test. Bivariate relations
were assessed by Pearson’s (r) or Spearman’s (rho) cor-
relation coefficients. A p−value < 0.05 was inferred
significant. All statistical tests were performed using
STATISTICA (data analysis software system), version
9.1. (StatSoft, Inc., Tulsa, Oklahoma, USA).
3. Results
3.1. Clinical and demographic subjects’
characteristics
Characteristics of the ALL survivors and the controls
were similar, except for significantly lower HDL-C and
insignificant tendencies to higher eGFR and lower per-
centage of smokers in the former ALL patients (Ta-
ble 1). Two out of 25 ALL survivors exhibited the pres-
ence of 2 diagnostic traits for the metabolic syndrome
by the National Cholesterol Education Program Adult
Treatment Panel III revised criteria [26].
3.2. Plasma dimethylarginines in ALL survivors
As compared with the controls, the ALL survivors
exhibited a significant, albeit small, increase in plasma
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Table 2
Plasma levels of dimethylarginines in ALL survivors and control subjects
Variable ALL survivors (n = 25) Controls (n = 20) p-value
ADMA (µmol/L) 0.63 ± 0.09 0.57 ± 0.07 0.016
SDMA (µmol/L) 0.60 ± 0.10 0.64 ± 0.10 0.17
ADMA/SDMA ratio 1.08 ± 0.22 0.91 ± 0.16 0.004
Data are shown as means ± SD; p-values <0.05 in bold. ADMA: asymmetric dimethy-
larginine; ALL: acute lymphoblastic leukemia; SDMA: symmetric dimethylarginine.
Fig. 1. Elevated plasma levels of asymmetric dimethylarginine (ADMA) (solid bars) but not symmetric dimethylarginine (SDMA) (empty bars),
with a consequently increased ADMA to SDMA ratio (hatched bars) in young adult survivors of childhood acute lymphoblastic leukemia (ALL)
compared with healthy controls. Values are presented as means and SEM. NS: not significant.
levels of ADMA, but not SDMA, with a consequent
elevation of theADMA to SDMAratio (Table 2;Fig. 1).
We found no interaction effects between former ALL
and gender or smoking on ADMA (p for interaction:
0.75 and 0.38, respectively, by a two-way ANOVA)
and SDMA (respective p-values: 0.17 and 0.33). The
results did not substantially change following exclusion
of the smokers or 2 ALL survivors with 2 diagnostic
traits for the metabolic syndrome.
3.3. Correlates of plasma levels of dimethylarginines
For the two groups pooled together, ADMA corre-
lated moderately to reduced HDL-C (r = −0.42, p =
0.005) and weakly to body mass index (BMI) (r =
0.33; p = 0.03), whereas SDMA was associated with
higher creatinine (r= 0.44, p= 0.003) and lower eGFR
(r = −0.43; p = 0.004). ADMA and SDMA were
mutually unrelated (r = 0.21; p = 0.18) and did not
correlate with the remaining demographic, clinical and
biochemical features (listed in Table 1), age at ALL di-
agnosis, interval from ALL diagnosis and time elapsed
since the completion of chemotherapy (p > 0.15).
The significance of the intergroup differences in
ADMA was retained following inclusion of BMI as a
covariate to the one-way ANCOVA. However, the ef-
fect of former ALL on ADMA was attenuated (adjust-
ed intergroup p = 0.10 by ANCOVA) upon adjustment
for HDL-C (ADMA vs. HDL-C: β = −0.065± 0.030;
p = 0.03). The lack of between-group differences in
SDMA was maintained after controlling for eGFR.
4. Discussion
Our salient observation was a small yet signifi-
cant rise in ADMA levels in young adult survivors of
childhood-onset ALL.
4.1. Possible mechanisms of an increased plasma
ADMA to SDMA ratio in ALL survivors
Selective ADMA elevations along with unchanged
SDMA levels had been previously reported in young-
to-middle-aged subjects free of preexisting atheroscle-
rotic CV disease but with classical risk factors: hyper-
cholesterolemia (2-fold) [27], uncomplicated newly-
diagnosed essential hypertension (2-fold) [28], high-
normal blood pressure (by about 40%) [29] and un-
complicated type 2 diabetes mellitus (2-fold) [30]. An
increased plasma ADMA/SDMA ratio was linked to
overexpression of type I protein arginine N -methyl-
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transferases (PRMTs-I) (catalyzing ADMA but not
SDMA formation [18]) and/or depressed activity
of dimethylarginine dimethylaminohydrolase (DDAH)
(hydrolyzing over 80% of ADMA but inactive to
SDMA [18]) in endothelial cells exposed to angiotensin
II [31], native or oxidizedLDL (oxLDL) [32,33], tumor
necrosis factor-α [32], homocysteine [34] and high glu-
cose concentrations [35]. Although none of the study
subjects exhibited hypertension, diabetes or severe hy-
percholesterolemia,minor intergroupdifferences in pa-
tients’ characteristics previously accompanied by pref-
erential ADMA accumulation could contribute to rela-
tively small ADMA rises in the ALL survivors. Never-
theless, the latter appears unlikely because blood pres-
sure [28,29], LDL-C [27], homocysteine [34], glyco-
sylated hemoglobin/glucose [30,35], triglycerides [36]
and inflammatory status [37] were similar across both
the groups.
However, our former ALL patients exhibited sig-
nificantly lower HDL-C levels, ADMA was correlat-
ed to reduced HDL-C (in agreement with data from
the largest cohort of young healthy adults with mea-
sured ADMA [38]) and this association partially ex-
plained ADMA elevations in the ALL survivors. De-
pressed HDL-C might facilitate ADMA accumulation
because prior exposure of cultured endothelial cells to
HDL counteracted the oxLDL-dependent inhibition of
DDAH expression and activity, with a consequently
lower ADMA level in the culture supernatant [39].
Furthermore, a lower HDL-C concentration, a part
of atherogenic dyslipidemia, might indicate insulin
resistance, known to be associated with elevated
ADMA [40]. Admittedly, metabolic sensitivity to in-
sulin was not quantified in the present study. On the
other hand, none of our patients met the metabolic syn-
drome criteria [26], exclusion of 2 formerALL patients
with 2 metabolic syndrome diagnostic traits produced
similar results, and waist circumference, waist-to-hip
ratio, BMI and triglycerides did not differ between the
groups. These findings were presumably due to the a
priori exclusion of the patients treated with cranial irra-
diation, a major factor responsible for subsequent GH
deficiency and late insulin resistance [6]. Nevertheless,
insulin resistance, exhibited by long-term ALL sur-
vivors after combined chemotherapy and cranial radio-
therapy, is also present – even though less pronounced–
in those treated with chemotherapy alone [5].
In addition, as cultured endothelial cells release
more free ADMA than SDMA [41] – both of which
are liberated during breakdown of proteins contain-
ing dimethylated arginine residues [18] – enhanced
propensity to apoptosis and accelerated endothelial cell
turnover could also increase the ADMA/SDMA ratio.
Anthracyclines induced endothelial apoptosis [10,11]
(a correlate of endothelial dysfunction accompanying
aging [42]) and subsequently impaired endothelium-
dependent relaxation in rabbit mesenteric arteries [10],
which was implied as a probable basis for decreased
FMD in 14 young cancer survivors who had completed
chemotherapy 2 to 60 months before [9].
Over 2-fold selective ADMA elevations were recent-
ly reported in adults with hematological malignancies,
including ALL, before onset of chemotherapy [22].
This finding was hypothetically linked with increased
turnover of tumor cells, extensive protein catabolism
and inflammatory activation [22], neither of which was
operative in our asymptomatic long-term survivors of
childhood ALL. Nevertheless, we are not able to ex-
clude persistent alterations of ADMA metabolism initi-
ated by a direct interference of chemotherapeutic agents
administered during childhood with cellular pathways
affecting ADMA elaboration.
4.2. Preferential ADMA accumulation – a marker of
endothelial oxidative stress?
Keeping in mind that at a normal function of the
kidney – the predominant route of SDMA elimina-
tion [18] – a higher ADMA/SDMA ratio can be per-
ceived as a rough indicator of reduced activity of
DDAH [30], a redox-sensitive enzyme decomposing
ADMA[43], we can set forth the speculative concept of
excessive intracellular oxidative stress as an early en-
dothelial abnormality in our youngALLsurvivorswith-
out renal pathology. Then a minor increase of ADMA
may be a starting point for its further gradual eleva-
tions [43]. Accordingly, ADMA may contribute to un-
coupling of endothelial NO synthase (eNOS), i.e., dis-
sociation of oxygen reduction by the reductase domain
from L-arginine oxidation by the oxygenase domain,
which converts eNOS from a source of NO into a super-
oxide generator [41,43–46]. Superoxide reacts avidly
with NO to form peroxynitrite that oxidizes tetrahydro-
biopterin, an essential eNOS cofactor, thus perpetuat-
ing eNOS uncoupling [43,46]. The presented sequence
of events increases intracellular oxidative stress that in
turn further promotes ADMA formation via increased
PRMTs-I expression [33] and/or reduced DDAH ac-
tivity [43]. This feed-forward reaction is presumably
interwoven with other positive feedback loops with
likely involvement of the local renin-angiotensin sys-
tem, endothelial membrane-bound nicotinamide ade-
74 J. Sulicka et al. / Elevated asymmetric dimethylarginine in young adult survivors of childhood acute lymphoblastic leukemia
nine dinucleotide phosphate (NADPH) oxidases and
the oxidant-sensitive nuclear factor-κB-regulated pro-
inflammatory transcription pathway [31,41,46,47], all
of which converge to promote endothelial dysfunction
and monocyte-endothelial interactions, early steps in
atherogenesis. A recent experimental study by Jacobi
et al. [48] provided proof-of-principle that ADMA –
more than a disease marker – is one of culpritmolecules
in atherogenesis.
4.3. Can small ADMA elevations be a very early
herald of late CV morbidity in long-term ALL
survivors?
Regardless of the mechanisms involved in preferen-
tial accumulation ofADMAover SDMA in young adult
survivors of childhood ALL, a key question is whether
this small rise in ADMA may translate to future adverse
CV events. However, in 1,808 healthy participants of
the Cardiovascular Risk in Young Finns Study with-
out atherosclerotic CV disease, baseline ADMA was
predictive of peripheral endothelial dysfunction mea-
sured after 6 years and the multivariate longitudinal
inverse association between ADMA and endothelium-
dependentvasodilation appeared stronger than in cross-
sectional analysis [49]. Moreover, in 880 middle-aged
women recruited to the Population Study of Women in
Gothenburg in the late 1960s, those in the top quintile
of baseline ADMA exhibited a cumulative relative haz-
ard of myocardial infarction and stroke of 1.75 com-
pared with the bottom four-fifths over a 24-year follow-
up [21]. Importantly, separation of the cumulative risk
curves for these CV events was observed not earlier
than at about 13 years [21]. It is noteworthy that each
0.15 μmol/L increase in ADMA (by 1 SD) was asso-
ciated with a 30% increase in incident myocardial in-
farction and stroke [21], which suggests potential clin-
ical importance of relatively small changes in ADMA.
Therefore it may be hypothesized that in young healthy
subjects even minor ADMA elevations within the nor-
mal range, as in our ALL survivors, might be a hall-
mark of early abnormalities which – on a long-term
basis – can lead to clinically overt atherosclerosis.
4.4. Limitations of the study
Several limitations to this study need to be acknowl-
edged. First, a small number of the participants in-
evitably constrains the conclusions based on only a
single measurement of dimethylated L-arginine ana-
logues. Moreover, we are fully aware of the fact that
repeated assays of ADMA and SDMA over time would
strengthen prognostic implications of our findings with
regard to the risk of future CV events. However, con-
trary to previous reports of endothelial dysfunction in
childhood malignancy survivors [9,13,50], we found
elevated ADMA, a biochemical marker of impaired
endothelial function, in the former ALL patients who
had been treated with a uniform chemotherapy pro-
tocol, which was likely to limit at least one source
of data variability. Second, the percentage of self-
reported smokers was insignificantly higher in the con-
trol group. Smoking is associated with endothelial dys-
function [14] and there are inconsistent data on the re-
lationship between smoking and ADMA levels [19–
21,38,51–53]. Nevertheless, we demonstrated neither
a significant effect of smoking on ADMA, nor in-
teractions between smoking status and ALL history,
which could result from a probably relatively short ex-
posure to tobacco smoke in the young study partici-
pants. Third, we did not exclude GH deficiency, a con-
dition associated with selective rises in ADMA and un-
changed SDMA levels [54]. Although GH deficiency
was linked predominantly to cranial radiotherapy [6],
yet hypothalamic-pituitary insufficiency may occur al-
so in long-term survivors of childhood cancer treated
with no cranial or total body irradiation [6,7]. On the
other hand, subjects’ height was similar in both our
groups, which argues against considerable impairment
of the GH-dependent axis in the ALL survivors.
5. Conclusions
ADMA is slightly elevated in young adult survivors
of childhood ALL. This preliminary finding can reflect
late detrimental effects of chemotherapy on the vascular
endotheliumor other as yet unknown target cells, in part
related to minor changes in the lipid profile. Whether
these subtle ADMA elevations might be a very early
herald of future CV morbidity, remains to be elucidated
in a prospective study.
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